<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139675">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02073682</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-D-U311</org_study_id>
    <nct_id>NCT02073682</nct_id>
  </id_info>
  <brief_title>Cancer Venous Thromboembolism (VTE)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Edoxaban will be similar to dalteparin in preventing recurrence of acute VTE following an
      initial index event in cancer subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>incidence of recurrent VTE at end of study</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>primary efficacy outcome is incidence of recurrent VTE at end of study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of of clinically relevant bleeding while on treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>primary safety outcome is incidence of clinically relevant bleeding while on treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Venous Thromboembolism (VTE)</condition>
  <condition>Deep Vein Thrombosis (DVT)</condition>
  <condition>Pulmonary Embolism (PE)</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>edoxaban group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>edoxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dalteparin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dalteparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>edoxaban</intervention_name>
    <arm_group_label>edoxaban group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <arm_group_label>dalteparin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with age â‰¥ 18 years or the otherwise legal lower age
             according to the country of residence;

          -  Confirmed acute lower extremity proximal DVT or PE for which long term treatment with
             low molecular weight heparin (LMWH) is indicated;

          -  Cancer, other than basal-cell or squamous-cell carcinoma of the skin;

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat
             the current (index) episode of DVT and/or PE;

          -  Treatment with therapeutic doses of an anticoagulant other than that used for
             pretreatment of the current (index) VTE episode prior to randomization;

          -  Active bleeding or high risk for bleeding contraindicating treatment with LMWH or
             edoxaban;

          -  Any other contraindication listed in the local labeling of dalteparin, enoxaparin, or
             edoxaban;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
